Loading company…
Senno Therapeutics develops iPSC-based cell therapies for severe liver failure.
Senno Therapeutics uses human induced pluripotent stem cells to develop liver progenitor cells and liver organoids for severe liver failure. Its research originated at the University of Tokyo's Institute of Medical Science. Founded in 2024 and based in Tokyo, Japan, the company raised venture funding in April 2026, led by Saisei Ventures with participation from One Capital and Mizuho Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in